Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005
- PMID: 17942652
- PMCID: PMC2168569
- DOI: 10.1128/JCM.00740-07
Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005
Abstract
Surveillance of Helicobacter pylori antimicrobial susceptibility reflecting the general population in Japan is limited. The antimicrobial susceptibilities of 3,707 H. pylori strains isolated from gastric mucosa samples of previously untreated patients diagnosed with gastroduodenal diseases at 36 medical facilities located throughout Japan between October 2002 and September 2005 were evaluated. Using an agar dilution method for antimicrobial susceptibility testing of H. pylori, the MIC distributions and trends during the study period for clarithromycin, amoxicillin, and metronidazole were studied. While the MIC(50) and MIC(90) for clarithromycin did not change during the 3-year period, the MIC(80) showed a 128-fold increase. Furthermore, the rate of resistance increased yearly from 18.9% (2002 to 2003) to 21.1% (2003 to 2004) and 27.7% (2004 to 2005). With a resistance rate of 19.2% among males compared to 27.0% among females, a significant gender difference was observed (P < 0.0001). Our study shows that in Japan, there is an evolving trend towards increased resistance to clarithromycin with geographical and gender differences as well as between clinical disease conditions. No significant changes in resistance were observed for amoxicillin and metronidazole during the period. While the benefit of H. pylori antimicrobial susceptibility testing has been debated in Japan, current empirical regimens are not based on susceptibility data representative of the general population. The development of an effective H. pylori eradication regimen in Japan will require continued resistance surveillance as well as a better understanding of the epidemiology of resistance.
Similar articles
-
Dynamics of antimicrobial resistance of Helicobacter pylori isolates in the Smolensk region of Russian Federation.Helicobacter. 2018 Dec;23(6):e12545. doi: 10.1111/hel.12545. Epub 2018 Oct 16. Helicobacter. 2018. PMID: 30324756
-
[Antimicrobial susceptibility tests and resistant strain of Helicobacter pylori].Kansenshogaku Zasshi. 2003 Apr;77(4):187-94. doi: 10.11150/kansenshogakuzasshi1970.77.187. Kansenshogaku Zasshi. 2003. PMID: 12739371 Japanese.
-
Susceptibilities to clarithromycin, amoxycillin and metronidazole of Helicobacter pylori isolates from the antrum and corpus in Tokyo, Japan, 1995-2001.Clin Microbiol Infect. 2005 Apr;11(4):307-11. doi: 10.1111/j.1469-0691.2005.01099.x. Clin Microbiol Infect. 2005. PMID: 15760428
-
[Drug resistant H. pylori in Japan: general remarks].Nihon Rinsho. 2005 Nov;63 Suppl 11:198-202. Nihon Rinsho. 2005. PMID: 16363531 Review. Japanese. No abstract available.
-
Helicobacter pylori antimicrobial resistance in Melbourne, Australia. Time to review therapeutic guidelines?Intern Med J. 2021 Nov;51(11):1919-1926. doi: 10.1111/imj.15355. Intern Med J. 2021. PMID: 33977647 Review.
Cited by
-
Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan.World J Gastrointest Pharmacol Ther. 2012 Feb 6;3(1):1-6. doi: 10.4292/wjgpt.v3.i1.1. World J Gastrointest Pharmacol Ther. 2012. PMID: 22408744 Free PMC article.
-
Current recommendations for Helicobacter pylori therapies in a world of evolving resistance.Gut Microbes. 2013 Nov-Dec;4(6):541-8. doi: 10.4161/gmic.25930. Epub 2013 Aug 5. Gut Microbes. 2013. PMID: 23929066 Free PMC article. Review.
-
Meta-analysis: High-dose vs. low-dose metronidazole-containing therapies for Helicobacter pylori eradication treatment.PLoS One. 2018 Jan 25;13(1):e0189888. doi: 10.1371/journal.pone.0189888. eCollection 2018. PLoS One. 2018. PMID: 29370199 Free PMC article.
-
Helicobacter pylori Therapy in the West.Jpn J Helicobacter Res. 2012;13(2):4-9. Jpn J Helicobacter Res. 2012. PMID: 28133585 Free PMC article.
-
Population-based strategies for Helicobacter pylori-associated disease management: a Japanese perspective.Expert Rev Gastroenterol Hepatol. 2010 Apr;4(2):149-56. doi: 10.1586/egh.10.7. Expert Rev Gastroenterol Hepatol. 2010. PMID: 20350262 Free PMC article.
References
-
- Alarcon, T., D. Domingo, and M. Lopez-Brea. 1999. Antibiotic resistance problems with Helicobacter pylori. Int. J. Antimicrob. Agents 12:19-26. - PubMed
-
- Asaka, M., K. Satoh, K. Sugano, T. Sugiyama, S. Takahashi, Y. Fukuda, H. Ota, K. Murakami, K. Kimura, and T. Shimoyama. 2001. Guidelines in the management of Helicobacter pylori infection in Japan. Helicobacter 6:177-186. - PubMed
-
- Boyanova, L., R. Koumanova, G. Gergova, M. Popova, I. Mitov, Y. Kovacheva, S. Derejian, N. Katsarov, R. Nikolov, and Z. Krastev. 2002. Prevalence of resistant Helicobacter pylori isolates in Bulgarian children. J. Med. Microbiol. 51:786-790. - PubMed
-
- Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard—7th edition. M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
-
- Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical